Vanguard Global Advisers
AVIR icon

Vanguard Global Advisers’s Atea Pharmaceuticals AVIR Stock Holding History

Vanguard Global Advisers’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Hold
25,681
– – ﹤0.01% 2704
2026
Q1 		$138K Buy
+25,681
New +$118K ﹤0.01% 2590

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Global Advisers's AVIR Position: Q2 2026 in Review

Vanguard Global Advisers held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 25,681 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #2704.

Vanguard Global Advisers first reported a position in AVIR in Q1 2026 and has held it in 2 quarters since. The position peaked at $138K in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Vanguard Global Advisers held 25,681 shares of Atea Pharmaceuticals worth $119K as of Q2 2026.
  • Vanguard Global Advisers left its Atea Pharmaceuticals share count unchanged in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2704 holding.
  • Vanguard Global Advisers first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Atea Pharmaceuticals position peaked at $138K in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.